Clinical Trials

33 enrolled

Breast Neoplasms

NCT04524000 2026-04-08

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

24 enrolled

Advanced Breast Cancer

NCT04796623 2026-04-08

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

122 enrolled

HR-positive, HER2-negative Advanced Breast Cancer

NCT06760819 2026-04-08

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT04544189 2026-04-02

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

69 enrolled

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

60 enrolled

Breast Neoplasms

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

150 enrolled

Unresectable Locally Recurrent Breast Cancer

NCT07498478 2026-03-27

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

94 enrolled

Breast Neoplasms

NCT06428396 2026-03-24

LITESPARK-029

120 enrolled

Breast Neoplasms

NCT04539938 2026-03-23

HER2CLIMB-04

70 enrolled 23 charts

Breast Neoplasms

NCT07487519 2026-03-23

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

180 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04576455 2026-03-20

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

303 enrolled 23 charts

Breast Neoplasms

NCT06188559 2026-03-20

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

135 enrolled

Breast Neoplasms

NCT06157892 2026-03-17

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

172 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

120 enrolled

Triple Negative Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

125 enrolled

Breast Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT07459738 2026-03-10

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

60 enrolled

Breast Neoplasms

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

72 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04191135 2026-03-03

KEYLYNK-009

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07072728 2026-03-03

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

BreastDermatologicGastrointestinalGenitourinaryGynecologic

87 enrolled

Adjustment Disorders, Breast Neoplasms, Kidney Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07446049 2026-03-03

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

BreastGastrointestinalGynecologicThoracic

180 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

83 enrolled

Triple Negative Breast Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT07427394 2026-02-23

SERENA-1b

24 enrolled

Advanced Breast Cancer

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

80 enrolled

Phase 2 Enrolling by invitation

Triple Negative Breast Neoplasms

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

60 enrolled

TNBC

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

100 enrolled

Breast Neoplasms

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors